Orion
Building well-being
1
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Your primary source for what Orion is about:
Suomeksi: www.orion.fi
In English: www.orion.fi/en
2
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Basics about Orion
• Name: Orion Oyj / Orion Corporation
• Businesses: pharmaceuticals (94%) and diagnostic tests (6%)
• Deep roots in Finland:
• Established in 1917 as ‘Lääketehdas Orion Oy’, in Helsinki.
Re-established in 2006 after a demerger of the former Orion
• Operational locations in Espoo, Turku, Kuopio, Hanko and Oulu
• European-wide presence with over 20 marketing companies
under names Orion Pharma and Orion Diagnostica
• Products
• About 300 medicines and self-care products (Orion Pharma)
• Active pharmaceutical ingredients, API (Fermion)
• Diagnostic tests (Orion Diagnostica)
•
•
•
•
3
Market leader in Finland with 10% market share
Recognised world-wide as a specialist in Parkinson’s Disease
Listed on Nasdaq OMX Helsinki
President & CEO: Timo Lappalainen
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Some figures
4
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Orion in the light of key figures
Net sales, EUR million
International operations, % of net sales
Operating profit (EBIT), EUR million
EBIT % of net sales
R&D expenses, EUR million
R&D % of net sales
Employees at the year-end
In terms of net sales, Orion ranks nr. 78 among global pharma.
The figures for 2011 will be disclosed on 7 February 2012.
5
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
2010
2009
850
772
73%
71%
254
207
30%
27%
86
95
10%
12%
3 131
3 147
Net sales are generated mainly in Europe
Breakdown of the EUR 850 million net sales for 2010
By business division
3%
By market area
5%
5%
44%
8%
Sales
through
partners
29%
12%
27%
13%
13%
35%
Proprietary Products
Specialty Products
Animal Health
Fermion
Contract manufacturing and other
Orion Diagnostica
6
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
35%
Finland
Scandinavia
Other Europe
North America
Other Markets
Half of Orion shares are held by Finnish
households
By number of shares
Non-profit
Organisations 6%
By number of votes
Financial and insurance
corporations 1%
Non-profit
Organisations 7%
Public sector
4%
Financial and insurance
corporations 1%
Public sector
7%
Private
corporations
8%
Households
50%
Foreign held and
nominee registered 31%
Private
corporations
14%
Households
65%
Foreign held and
nominee registered 6%
Altogether 141.3 million shares and over 57 000 shareholders. Both share classes are listed on NASDAQ OMX Helsinki since 1 July 2006–
Share A (ORNAV) has 20 votes/share and Share B (ORNBV) has 1 vote/share, in the AGM but they have equal rights to assets and dividends. The
market value of Orion Corporation at 31 December 2011 was about 2.2 billion €.
7
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Broad product
portfolio.
Some might be
familiar to you.
8
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Medicines ’over-the-counter’
9
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Nutritionals
10
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Non-medicinals, for personal care and hygiene
11
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Pharmacy cosmetics
12
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
For your pet
13
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Easyhaler® for inhaled asthma medicines
14
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Some background
about world
pharma industry
15
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Some facts about the pharmaceutical industry 1(2)
World sales 2010
IMS Health: USD 875 bn in wholesale value
Big multinationals
and local players
10 biggest companies make 40% of the world total.
Important role
in healthcare
16
(Pfizer, Sanofi, Merck (US), Novartis, GSK, Roche, AstraZeneca, J&J, Lilly, Abbott)
Safe, effective and better - and affordable - medicines.
Education of healthcare professionals
Innovation
Average R&D investment is 10-15% of net sales.
High regulation
High product responsibility. Compliance with Good
Practices (GxP) in manufacturing, laboratory, R&D
and marketing.
18.1.2012
The solutions to unmet medical needs are explored in companies,
with little if any public financing.
Anne Allo & Sirpa Pelttari / Orion Corporation
Some facts about the pharmaceutical industry 2(2)
Products
registered & authorised
Restrictions on
communication
Retail sales
through pharmacies
Challenge
of counterfeits
17
18.1.2012
All medicines shall be officially approved
for marketing and clinical use. National lists.
All promotional activities of prescription medicines are
addressed to healthcare professionals exclusively.
No consumer advertising on prescription medicines.
Sales arguments must be based on approved
product characteristics (= confirmed study results).
In most countries, medicines are only available
via pharmacies.
Counterfeit (falsified, fake) drugs are an increasing
global challenge. Trade in internet is very difficult
to control.
Anne Allo & Sirpa Pelttari / Orion Corporation
Orion’s strategy
How are we planning to manage?
18
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Orion concentrates own operations within Europe
Finland
Market leadership
Scandinavia
Strong domestic market position
Eastern Europe
Presence with branded generics
Western and Central Europe
Strong position with proprietary products
Southern Europe
Progress with proprietary products in
hospital markets
19
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Strategic aim:
Profitable growth and increased shareholder value
whilst keeping business risks under control
Partners
and networking
Flexible and efficient operations
M ANAGEMENT OF COMPLEXITY IN COST-EFFICIENT WAYS
20
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Networking and partnering throughout
the value chain
R&D
Supply Chain
• R&D partnerships and
networks cover all
phases from preclinical
to product registration
• Balances risks and
enables an increasing
number of new research
projects
21
18.1.2012
• Supply Chain operations
are global and
partnerships cover the
whole chain of
operations
• Improved efficiency by
“make or buy” decisions
Anne Allo & Sirpa Pelttari / Orion Corporation
Sales & Marketing
• Partnerships in sales and
marketing ensure a
broad network of
distribution channels
• Orion’s proprietary drugs
distributed worldwide
• Product portfolio
expanded by selling
partners’ products
We invest in R&D
to build our future
and
to fight illnesses
R&D is part of our mission
to build well-being
22
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Our main product looks simple, doesn’t it?
… But its road to market took over 10 years.
23
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
It’s all about an ideal molecule
The active substance in a
medicine is like a key in a
lock: it either opens or
closes a pathway, activates
or blocks its target, typically
a receptor in a cell.
Entacapone, Orion’s drug
discovery, acts on COMT,
a very common enzyme
present in the body.
24
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
The 7-17 year-long road of a molecule candidate
to a new drug
”Pipeline”
Research
Early development
Late stage
development
Target
identification
and validation
Lead Molecule
identification
Lead Molecule
optimisation
Molecule candidate
selection,
preclinical dev.
Clinical Phase I
in healthy humans
Clinical Phase II
in a small number
of real patients
Clinical Phase III
in a large number
of real patients
8–24 months
12–24 months
18–36 months
12–24 months
12–14 months
12–36 months
18–48 months
A partner company may join the work at any stage of the project
• In the R&D process, the compound’s efficacy as a treatment option for the target disease
•
•
•
•
•
25
and safety for the patient are explored with a purpose to confirm the compound’s
superiority to already existing medicines.
Each step is subject to approval of medicinal authorities (FDA or EMA).
The hundreds of parallel and sequential studies generate an enormous documentation
of detailed data.
If successful, the results are filed into a marketing application to EMA and/or FDA.
The review of the application takes 1-2 years. If OK, a marketing authorisation is granted.
The compound is patented at an early stage. The protection expires after 20 years.
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Pharmaceutical R&D takes:
Patience
Time
Money
Expertise
26
18.1.2012
One molecule in a million shows some promise.
Only 20-30 completely new drugs (NCEs/NBEs)
are approved/introduced annually
It takes at least 10–15 years to develop a completely
new drug from idea to market
The average cost of developing a new drug
is USD 700 million. The risk of failure is high
Ca. 115 000 scientists and other industry staff members
are engaged in pharma R&D in the EU alone
Anne Allo & Sirpa Pelttari / Orion Corporation
Pharmaceutical R&D also gives:
New treatments
Knowledge
Money
Healthcare economics
Innovation
27
18.1.2012
Every new treatment gives more hope to manage
with a disease. For the patients and their caregivers
it also means improved quality of life.
Understanding of diseases and their mechanisms
accumulates with every single study.
Even failed projects add our knowledge.
The R&D investment generates earnings
some years after the new product’s launch.
Effective medicinal treatments may save
expensive days at hospital, e.g.
Discoveries generate more disoveries to solve unmet
medical needs of challenging diseases.
Anne Allo & Sirpa Pelttari / Orion Corporation
Orion’s R&D activity
• Orion is one of Finland’s biggest investors in R&D
– R&D costs are ca. 10% of our net sales
Research staff accounts for 20% of our total workforce
• Our purpose is to introduce new innovative treatments to
global markets
• Since late 1980’s we have developed 7 molecules into
commercialised medicines. They now generate 50% of our
net sales
• We currently explore new medicinal approaches for:
–
–
–
–
28
18.1.2012
central nervous system disorders
cancer
critical care
respiratory diseases (inhalable drugs)
Anne Allo & Sirpa Pelttari / Orion Corporation
Proprietary products generated 50%
of Orion’s net sales for 2010
Product
Indication
Stalevo®, Comtess® and Comtan®
(entacapone)
Parkinson’s Disease
253
Simdax® (levosimendan)
Severe heart failure
40
Easyhaler® product family
(beclomethasone, budesonide,
formoterol)
Asthma, COPD
28
Dexdor® and Precedex®
(dexmedetomidine)
Sedative for patients
in intensive care
27
Dexdomitor®, Domitor®, Domosedan® and
Antisedan® (dexmedetomidine,
detomidine, atipamezole )
Animal sedatives
24
Divina® range (estrogen)
Menopausal symptoms
13
Fareston® (toremifene)
Breast cancer
12
Total
% of pharmaceutical net sales
29
18.1.2012
EUR
million
2010
Anne Allo & Sirpa Pelttari / Orion Corporation
397
49 %
Some helpful terms
30
OTC product (over the
counter)
Can be bought without doctor’s prescription
Proprietary product
A medicine developed in-house all the way
throughout the pipeline. The originator holds full
rights for the product until patent expiry.
Generic medicine
Off-patent. A medicine whose patent has expired.
Can be copied by anyone.
NCE, NBE
New Chemical (Biological) Entity. An active
substance based on a completely new chemical
or biological mechanism of action
API
Active Pharmaceutical Ingredient, the substance
that induces the medicinal effect of the drug
Marketing authorisation
(MA)
The license granted by a medicinal authority
(FDA, EMA, Fimea, e.g.) to sell a drug
Pipeline
New drug development process all the way
through preclinical and clinical phases
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Orion and the
environment
Sirpa Pelttari 16.1.2012
31
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Environmental legislation: important acts,
decrees and decisions for Orion
• Environmental protection act 4.2.2000/86
— Act on Changing the Environmental Protection Act 647/2011 enters into force
1.5.2012
• Environmental Protection Decree 18.2.2000/169
• Old Waste Act 1072/1993
• New Waste Act 646/2011 enters into force on 1.5.2012
• Waste Decree 1390/1993
• VOC Decree 435/2001, Government Decree on the limitation of emissions of
volatile organic compounds due to the use of organic solvents in certain activities
and installations
• Government Decree on Substances Dangerous and Harmful to the Aquatic
Environment 1022/2006
• Government decison on information to be provided on hazardous waste and the
packing and labelling of hazardous waste 659/1996
• Ministry of the Environment Decree on the list of the most common wastes and of
hazardous wastes 1129/2001
• Chemicals Act 744/1989
• Nature Conservation Act 1096/1996
32
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Environmental Protection Act
General principles provided in Section 4 for activities that pose a risk of pollution:
1) Pollution prevention and minimizing harmful impact: harmful environmental
impact shall be prevented or, when it cannot be prevented completely, reduced
to a minimum
2) Caution and care: proper care and caution shall be taken to prevent pollution
as entailed by the nature of the activity, and the probability of pollution, risk of
accident and opportunities to prevent accidents and limit their effects shall be
taken into account
3) Best available techniques, BAT: the best available technique shall be used
4) Best environmental practice: combinations of various methods, such as work
methods, shall be used and such raw materials and fuels shall be selected as
provide appropriate and cost-efficient means to prevent pollution
• ‘Polluter pays’: It is the duty of parties engaged in activities that pose a risk of
pollution to prevent impact and eliminate or minimize harmful environmental
effects
33
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Environmental Protection Act
• General duties provided in Section 5
1) Knowledge requirement: Operators must have sufficient
knowledge of their activities' environmental impact and risks
and of ways to reduce harmful effects
2) Obligation to prevent pollution: If the activities cause or
may directly result in environmental pollution, the operator
must take the appropriate action without delay in order to
prevent pollution, or, if pollution has already resulted, to
reduce it to a minimum (385/2009)
3) In addition, the general duties and principles laid down
Chapter 2 of the Waste Act (646/2011) must be observed in
activities posing a risk of pollution. (647/2011)
34
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Environmental Protection Act
• General permit requirement provided in Section 28:
1) Environmental permit: A permit is required for activities
that pose a threat of environmental pollution. Activities
subject to a permit are prescribed in more detail by
decree.
35
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
New Waste Act 2011
• The new Waste Act and ca. 20 other acts linked to it
were confirmed on 17.6.2011.
• Those acts will enter into force on 1.5.2012.
• The acts have been published in Statutes of Finland
(Suomen säädöskokoelma), numbers 646-666/2011.
• The purpose is to harmonise the waste legislation in
line with today’s waste and environmental policies and
the requirements of EU legislation.
36
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Waste hierarchy
A waste hierarchy which complies with the EU Waste Directive
(2008/98/EC) and specifies the priority of measures concerning the
amount of waste, harm mitigation, and waste management:
1. Preventing the emergence of waste
2. Re-using items as such, e.g. metal barrels
3. Recycling waste as material, e.g. polyethylene plastic
4. Utilising waste as energy; energy waste is combustible waste
5. Safe landfill disposal of waste
• Waste that cannot be disposed of by other means, e.g.
grease trap sludge
37
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Orion operates under environmental permits
• Environmental permits are
required for Orion’s
pharmaceutical manufacturing
operations, as specified in the
Environmental Protection
Decree of Finland.
• The environmental permits are
granted and supervised by
regional environmental
authorities.
38
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Orion’s main site and headquarters are in Espoo
39
Orion’s site in Espoo is located in Mankkaa, next to the Tapiola sports park.
About halfAnne
of Allo
the& Sirpa
Group’s
18.1.2012
Pelttari /employees
Orion Corporationwork here.
Orion’s Turku site
Orion’s manufacturing operations in Turku include certain tablets, hormonal products, cancer
medicines
and basic ointments. A major research centre is here too.
18.1.2012
40
Anne Allo & Sirpa Pelttari / Orion Corporation
Fermion’s Hanko plant
Fermion is a so-called fine chemicals manufacturer. It produces active ingredients
for pharmaceuticals in chemical synthesis at its plants in Hanko and Oulu.
41
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Orion’s environmental activities
• Our environmental management focus
is on the following areas:
—
—
—
—
—
Waste and materials management
Air and soil protection
Energy and water consumption
Wastewater
Environmental burden of our products
• We monitor the environmental
impacts of our operations by e.g
— measuring and calculating the
volumes of chemicals, solvents and
other substances, consumption of
packaging materials, water and
energy, emissions into water and air
and
— keeping track of waste and recording
waste statistics.
42
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
ISO 14001 based system under construction
• Orion wants to overperform the minimum requirements set by laws and
regulations for environmental affairs
• Orion publishes GRI-compliant Sustainability Reports since 2009.
The ones for 2009 and 2010 are accessible at www.orion.fi/sustainability
— Our management approaches and performance indicators of environmental
responsibility are presented here.
• An ISO 14001 based environmental management system is currently
being built for Orion, first comprising the pharmaceutical preparations
business (Espoo, Turku and Kuopio plants).
More systematic practices and continuous improvement in
environmental affairs
• An Environmental Policy will be confirmed for Orion in Q1/2012.
43
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Orion’s current environmental engagements
• Responsible Care (RC)
– Orion is a member of Responsible Care, the global voluntary initiative
under which chemical industries work together to continuously
improve their health, safety and environmental performance.
– Environmental performance is reported annually to RC
• Energy Efficiency Programme of EK
– As a member in the Energy Efficiency Programme initiated and
coordinated by the Confederation of Finnish Industries (EK)Orion aims
to cut its proportional energy consumption by 9 per cent by 2016,
compared with the 2005 level. This includes the consumption of
electricity, heating energy and fuels.
• Carbon Disclosure
– Orion reports its CO2 emissions to the Carbon Disclosure Project, CDP
44
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Orion’s environmental impacts
• The manufacturing processes of
pharmaceutical products, active
pharmaceutical ingredients (API)
and diagnostics products differ
very much from each other.
Accordingly, they also
consume materials and
generate emissions and waste
differently both in terms of
amounts and types.
Common to all is
• Uncompromised cleanliness
• Massive air conditioning systems
45
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Absolute cleanliness is a must
46
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Water consumption and discharges
Water consumption
• Orion is a heavy user of
water. Most of the water
goes to washing the
production equipment.
• The waste waters from are
drained to municipal
treatment plants in
accordance with agreements
with environmental
authorities.
• Fermion’s Hanko plant has
its own water purification
plant where waste water is
pre-treated before drained
to the municipal treatment
system.
47
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Water discharges
Solid waste
• Orion monitors its waste volumes using three indicators:
1)
hazardous waste to be transported for disposal
2)
recovered waste to be recycled, including energy waste and
3)
landfill waste
• All such solid waste as contains pharmaceuticals is classified as
hazardous waste and is sent to Ekokem Oy at Riihimäki
— Fermion produces the relatively largest amount of Orion’s total hazardous
waste
• The Espoo, Turku and Kuopio operations produce mostly non-hazardous
recyclable materials and landfill waste. About 20% of their total solid
waste is hazardous.
• Orion aims to reduce waste by all applicable means.
48
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Orion’s objectives in waste management
• Orion's objectives to reduce the production of waste are aligned
with the priority targets specified in the EU-level waste strategy
(waste hierarchy of the Directive 2008/98/EC on waste, Waste
Framework Directive), which are included in the New Waste Act.
• Avoiding the production of waste by all possible means
• Efficient sorting and recycling of the produced waste materials
• Hereby we also decrease the cost of waste.
• Seeking ways to re-use materials
• Minimised landfill waste.
49
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Emissions into air
• Since 2007, companies in Finland have had to comply with very stringent
emission limits for VOC quantities and concentrations. (Government Decree
on the limitation of VOC emissions due to the use of organic solvents in certain
activities and installations, 435/2001 at the end of October 2007)
• Orion’s VOC emissions come from several solvents used by Fermion in its
chemical synthesis processes, and mainly ethanol used in tablet mass
production and tablet coating in the Turku and Espoo plants
― Fermion accounts for ca. 97% of the total solvents used by Orion, and for about
75% of Orion’s total VOC emissions.
― Thanks to process investments in Hanko and Oulu, Orion’s total VOC emissions
dropped dramatically from 2007 (in 2010 we experienced some technical
problems at Fermion’s Oulu plant).
• Very small amounts of dust.
• Combustion gases from the steam boiler of Espoo and Kuopio. The sulphur
content of the oil is low (less than 1%)
• CO2 emissions are reported for direct and indirect energy comsumption
50
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Environmental challenges for Orion to cope with
• We try to minimize the use of volatile organic solvents by changing
processes.
• We are studying possibilities to burn the volatile solvents that evaporate
from the tablet manufacturing processes and get mixed with the outlet
air.
― Today, more than 90% of the volatile solvents in the plants of Espoo and Turku
pass through the gas scrubbers into waste waters.
• An important goal for Orion is to continuously reduce emissions in the
waste water and particularly the amount of harmful substances in them.
― The means to achieve this include more efficient pre-cleaning of the
manufacturing equipment.
• Even better control of energy and water consumption (heat recovery
systems, e.g.).
51
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Orion building
environmental
well-being with
HH students
52
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
The world’s top 20 pharmaceutical companies
53
1-10
http://
Pfizer
www.pfizer.com
Sanofi
www.sanofi.com
Merck & Co
www.merck.com
Novartis
www.novartis.com
GlaxoSmithKline
www.gsk.com
Roche
www.roche.com
AstraZeneca
www.astrazeneca.com
Johnson&Johnson
www.jns.com
Eli Lilly & Co
www.lilly.com
Abbott
www.abbott.com
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
The world’s top 20 pharmaceutical companies
54
11-20
http://
Bristol-Myers Squibb
www.bms.com
Teva
www.tevapharm.com
Amgen
www.amgen.com
Bayer
www.bayer.com
Takeda
www.takeda.com
Boehringer Ingelheim
www.boehringer-ingelheim.com
Astellas
www.astellas.com
Novo Nordisk
www.novonordisk.com
Daiichi Sankyo
www.daiichisankyo.com
Eisai
www.eisai.com
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Finland’s top 20 pharmaceutical companies
1-10
http://
Orion
www.orion.fi
Pfizer
www.pfizer.fi
(MSD)
( www.msd.fi ) fuusio US-Merckin kanssa
GlaxoSmithKline
www.glaxosmithkline.fi/
AstraZeneca
www.astrazeneca.fi/
Sanofi
www.sanofi.fi
Novartis
www.novartis.fi
Roche
www.roche.fi
Leiras
www.leiras.fi
Abbott
www.abbott.fi
www.bmsfinland.fi/
55
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Finland’s top 20 pharmaceutical companies
11-20
56
Novo Nordisk
www.novonordisk.fi
Ratiopharm
www.ratiopharm.fi
Bayer Schering
www.bayer.fi
Lilly
www.lilly.fi
Boehringer Ingelheim
www.boehringer-ingelheim.fi
Janssen-Cilag
www.janssen.fi
Amgen
www.amgen.com
Actavis
www.actavis.fi
Lundbeck
www.lundbeck.fi
Baxter
www.baxter.fi
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
These companies are also interesting ones
http://
Merck KGaA
www.merckgroup.com
Shire
www.shire.com
Leo Pharma
www.leo-pharma.com
Santen
www.santen.com
Meda
www.meda.se
Indian pharmaceutical companies
57
Sun
www.sunpharmaceuticals.com
Dr Reddy’s
www.drreddys.com
Wockhardt
www.wockhardt.com
Aurobindo
www.aurobindo.com
Ranbaxy
www.ranbaxy.com
Torrent
www.torrentpharma.com
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Contact Anne & Sirpa
58
Anne Allo
Corporate Responsibility Officer
Sirpa Pelttari
EHS Specialist
Orion Oyj | Orion Corporation
P.O.Box 65, 02101 Espoo
Orionintie 1 A, 02200 Espoo
Orion Oyj | Orion Corporation
P.O.Box 65, 02101 Espoo
Orionintie 1 A, 02200 Espoo
+358 50 966 3735
+358 10 426 3735
+358 50 966 3118
+358 10 426 3118
anne.allo@orion.fi
Sirpa.pelttari@orion.fi
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation
Welcome onboard
to building wellbeing with us!
59
18.1.2012
Anne Allo & Sirpa Pelttari / Orion Corporation